Home>>Signaling Pathways>> Others>> Estrogen Receptor/ERR>>(R)-Equol

(R)-Equol (Synonyms: (+)-Equol, Isoequol)

Catalog No.GC40643

Equol is a non-steroidal estrogen produced from the metabolism of the isoflavonoid phytoestrogen daidzein by human intestinal microflora.

Products are for research use only. Not for human use. We do not sell to patients.

(R)-Equol Chemical Structure

Cas No.: 221054-79-1

Size Price Stock Qty
1mg
$15.00
In stock
5mg
$69.00
In stock
10mg
$122.00
In stock
25mg
$268.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

(R)-Equol is an agonist of both ERα and ERβ with Kis of 27.4 and 15.4 nM, respectively.

(R)-Equol is an agonist of both ERα and ERβ with Kis of 27.4 and 15.4 nM, respectively[1]. (R)-Equol induces a dose-dependent inhibitory effect on the invasive capacity of MDA-MB-231 cells that is significant at the highest concentration tested (50 μM). Following 48-h exposure to (R)-Equol, invasion is reduced by 62% (p=0.009, versus untreated cells) with 50 μM (R)-Equol. Matrix metalloproteinase-2 (MMP-2) expression is significantly down-regulated following treatment with 50 μM (R)-Equol (p=0.035)[2].

Animals fed (R)-Equol have a significantly reduced number of palpable tumors over time when compare with Controls (P=0.002). Furthermore, the number of palpable tumors formed per rat in the (R)-Equol-fed group is significantly lower than that of rats treated with S-(-)equol (P=0.008). (R)-Equol-fed animals have 43% fewer tumors than the control group and this difference is highly statistically significant (P=0.004). The number of tumors/tumor-bearing animal is significantly lower in the animals fed (R)-Equol compare with Controls (3.3±0.4 versus 5.5±0.5, P=0.004). At necropsy, the mean (±SEM) tumor weight per animal for (R)-Equol fed rats (5.3±1.1 mg) is significantly reduced (P=0.04) when compare with Controls (9.9±1.4 mg). Feeding the (R)-Equol diet results in significantly increased tumor latency (P=0.003)[3].

References:
[1]. Setchell KD, et al. S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr. 2005 May;81(5):1072-9.
[2]. Magee PJ, et al. Daidzein, R-(+)equol and S-(-)equol inhibit the invasion of MDA-MB-231 breast cancer cells potentially via the down-regulation of matrix metalloproteinase-2. Eur J Nutr. 2014 Feb;53(1):345-50.
[3]. Brown NM, et al. The chemopreventive action of equol enantiomers in a chemically induced animal model of breast cancer. Carcinogenesis. 2010 May;31(5):886-93.

Reviews

Review for (R)-Equol

Average Rating: 5 ★★★★★ (Based on Reviews and 14 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for (R)-Equol

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.